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Optimal vaccine strategies must be identified for improving T-cell vaccination against
infectious and malignant diseases. MelQbG10 is a virus-like nano-particle loaded with
A-type CpG-oligonucleotides (CpG-ODN) and coupled to peptide16–35 derived from Melan-
A/MART-1. In this phase IIa clinical study, four groups of stage III-IV melanoma patients
were vaccinated with MelQbG10, given (i) with IFA (Montanide) s.c.; (ii) with IFA s.c. and
topical Imiquimod; (iii) i.d. with topical Imiquimod; or (iv) as intralymph node injection. In
total, 16/21 (76%) patients generated ex vivo detectable Melan-A/MART-1-specific T-cell
responses. T-cell frequencies were significantly higher when IFA was used as adjuvant,
resulting in detectable T-cell responses in all (11/11) patients, with predominant genera-
tion of effector-memory-phenotype cells. In turn, Imiquimod induced higher proportions
of central-memory-phenotype cells and increased percentages of CD127+ (IL-7R) T cells.
Direct injection of MelQbG10 into lymph nodes resulted in lower T-cell frequencies, asso-
ciated with lower proportions of memory and effector-phenotype T cells. Swelling of vac-
cine site draining lymph nodes, and increased glucose uptake at PET/CT was observed in
13/15 (87%) of evaluable patients, reflecting vaccine triggered immune reactions in lymph
nodes. We conclude that the simultaneous use of both Imiquimod and CpG-ODN induced
combined memory and effector CD8+ T-cell responses.
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Introduction
Melanoma is associated with frequent spontaneous CD8+ T-cell
responses that may improve the clinical outcome of the disease.
Moreover, immunotherapy has demonstrated clinical benefit for
melanoma patients, particularly after adoptive T-cell transfer, or
treatment with anti-CTLA-4 antibodies [1–3]. CD8+ cytotoxic T
cells recognize a wide variety of tumor-associated antigens includ-
ing melanocytic differentiation antigens, shared tumor-specific
antigens, and mutated antigens, as listed in the T cell-defined
tumor antigen database at http://cancerimmunity.org/peptide/.
These antigens are presented as peptides by human leucocyte anti-
gen (HLA) molecules on the surface of tumor cells and antigen
presenting cells (APCs). The most potent inducers of T cells are
the dendritic cells (DCs), whichmust be activated by innate stimuli
and cytokines for optimal immunogenicity.
In contrast to passive immunization, active vaccination is thus
far unable to demonstrate clinical benefit in most studies [4,5].
Improvement of cancer vaccines depends on continued invest-
ments in research and development, and a better understanding of
innate and specific immune activation pathways [6,7]. Currently,
cancer vaccines are still relatively inefficient in the generation
of therapeutic T-cell responses; this is also the case for vaccines
against infectious diseases, where efficient and protective memory
and effector T-cell responses are rarely induced.
MelQbG10 is an innovative vaccine that integrates three com-
ponents essential for successful immunotherapy. First, MelQbG10
consists of an immunogenic virus-like nano-particle (VLP), that is
a protein shell with a diameter of 30 nm derived from the bac-
teriophage Qbeta that efficiently drains into local lymph nodes
for uptake and processing by DCs and macrophages [8]. Second,
the VLPs contain short immunostimulatory oligonucleotides called
G10, an unmodified A-type CpG-ODN triggering toll-like receptor
(TLR)-9, protected from DNAse attack by the VLP. And third, the
peptide16–35 of the antigenMelan-A/MART-1 is covalently coupled
to the VLP. The peptide is derived from the melanocyte differen-
tiation antigen Melan-A/MART-1, is part of the melanosome, and
is expressed in early and advanced melanoma lesions [9]. Upon
injection,MelQbG10 is taken up by DCs, whichmature and present
Melan-A/MART-1 peptides on their surface and activate cytotoxic
T lymphocytes (CTLs) [10], as well as Th cells [11]. T-cell activ-
ation is further promoted by the CpG-ODN G10 that trig-
gers B cells and plasmocytoid DCs via TLR-9. This results
in high-level expression of costimulatory molecules (CD80,
CD86) and secretion of various cytokines (e.g. IFN-α, TNF-α,
IL-12) supporting proliferation and maturation of immune
cells.
In a first clinical trial, we showed that vaccination with
MelQbG10 was well tolerated and can be used safely in melanoma
patients [10]. Proof-of-concept was provided by the induction of
tumor-specific CD8+ T cells after MelQbG10 vaccination [10].
Nevertheless, it is necessary to further improve immune responses
and clinical responses. The aim of the present study was to fur-
ther increase the immunogenicity of MelQbG10. Therefore, we
used Montanide ISA-51 (Incomplete Freund’s Adjuvant (IFA)), an
oil-based depot-like adjuvant widely applied to boost immuno-
genicity of various antigens in many animal models and in clin-
ical trials [12–14], and Imiquimod 5%, a cream that is known
to activate APCs, including plasmacytoid DCs, via TLR-7 in
the skin [15,16] to determine whether the immunogenicity of
MelQbG10 may be further enhanced by additional immune stim-
ulatory agents.
Results
Safety and tolerability
Twenty-one patients were enrolled, whereof 17 patients finished
the clinical trial according to protocol and four patients discon-
tinued earlier due to disease progression (one patient per group).
Baseline characteristics of the patients are shown in Supporting
Information Table 1. A total of 122 injections were applied accord-
ing to the four treatment regimens. The vaccine was generally well
tolerated with transient local reactions at the injection sites mostly
rated as of mild intensity. The 21 patients experienced a total of
187 adverse events (AEs). Of those, 12 events emerged between
screening and first vaccination. Sixty-two AEs (35%) were judged
by the investigator as of causal relationship to the study drug. Of
all AEs, 185 AEs were judged by severity, defined as mild, mod-
erate or severe: 154 (83%) of the AEs were mild, 30 (16.5%)
moderate and 1 (0.5%) severe. Six events were judged as serious
(SAEs according to ICH guidelines) that were hospitalizations due
to tumor progression. No SAE was considered to be related to the
study treatment. Most recognized AEs were local adverse reactions
(induration, pain, erythema, and swelling). Patients of treatment
groups I and II (with IFA) showedmore treatment related local AEs
(40 versus 22 AEs) than patients of groups III and IV (without IFA).
Injection site reactions were less frequent and milder after intra-
nodal injection than after i.d. or s.c. administration (Fig. 1). Pain
was predominant in patients receiving IFA, whereas erythema and
swelling was predominant in Imiquimod-treated patients. Most
local reactions were observed after the third injection in all treat-
ment groups. Fatigue and flu-like symptoms were mainly found in
IFA-treated patients (Table 1). Vital signs, ECGs, and laboratory
parameters were all unremarkable pre- and posttreatment.
T-cell frequencies
The primary aim of the study was to activate Melan-A-
specific CD8+ T cells. PBMCs were analyzed by flow cytometry
with fluorescent peptide/HLA-A2 tetramers. In total, 16
of 21 patients (76%) were immune responders to vac-
cination with MelQbG10, as defined by at least twofold
increased percentages of Melan-A tetramer positive cells after
start of vaccination in comparison to before [17]. T-cell
frequencies were increased in all 11 patients of treatment groups
I and II, that is after vaccination with MelQbG10 together with
IFA, with or without local application of Imiquimod (Fig. 2A–C
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Figure 1. Incidence of injection site reactions per treatment group. The number of patients with pain and/or itching and the number of patients
with a diameter ≥ 1 cm with regard to local erythema, swelling, and/or induration were enumerated in the available diary recordings. The results
are shown for each injection. (A) Group I: local reactions after 1 mg s.c injection of MelQbG10 with IFA (n = 5) and (B) Group II: with IFA and topical
Imiquimod 5% (n = 6); (C) Group III: i.d. injection with topical Imiquimod 5% (n = 5); and (D) Group IV: after ultrasound-guided intralymph node
injection (14/42/140 μg MelQbG10, n = 5).
and Supporting Information Table 2). Two patients in treatment
group III and three in treatment group IV also reached maximal
T-cell frequencies fulfilling the T-cell responder criteria. Never-
theless, in patients vaccinated without IFA but treated topically
with Imiquimod (group III) and by intranodal injection (group
IV) the T-cell frequencies were significantly lower as compared to
patients after MelQbG10 vaccinations with IFA (groups I and II,
p = 0.003).
Patient age varied slightly from patient group I to IV
(means of 58, 49, 61, and 56 years, respectively; Support-
ing Information Table 1). We cannot formally exclude that
these differences biased our results. However, it seems rather
unlikely, as there was no significant correlation; young patients
did not differ significantly from older patients with regard to
their T-cell frequencies (Supporting Information Table 2). This
finding fits with our recent results from another study also
Table 1. All adverse events with an incidence > 3, listed for each group with number of events and number of patients
Group I events Group II events Group III events Group IV events
Preferred term (patients) (patients) (patients) (patients)
General disorders and administration site conditions
Injection site induration 4(2) 15(5) 1(1)
Influenza-like illness 2(2) 2(1) 7(2)
Fatigue 4(3) 2(2) 10(4)
Edema peripheral 4(2) 1(1)
Skin and subcutaneous tissue disorders
Skin neoplasm excision 1(1) 8(3) 3(2)
Skin nodule 2(2) 5(3) 1(1) 3(2)
Blood and lymphatic system disorders
Lymphadenopathya) 1(1) 1(1) 6(4) 4(3)
a)Defined as clinically palpable or radiologically enlarged lymph nodes.
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Figure 2. Frequency and memory-
/effector-phenotype cell differentiation of
Melan-A/MART-1-specific T cells. PBMCs
were analyzed by flow cytometry directly
ex vivo, that is without prior in vitro
cultures. (A) Representative dot plot from
one patient out of 21 (patient 1001-group
I), showing staining for CD8 expression
and Melan-A/HLA-A2 tetramers. (B) T-cell
frequencies of the four patient groups,
before (Prevacc) and after vaccination
s.c. adjuvanted with IFA (group I, five
patients), IFA with topical Imiquimod
5% (group II, six patients), i.d. injection
with topical Imiquimod 5% (group III, five
patients) or intranodal injection (group
IV, five patients). (C) T-cell frequencies
for each patient, before vaccination and
the highest level reached after start of
vaccination. (D) Representative dot plot
from one patient of 21 (patient 1009, group
II) of gating of Melan-A-specific T cells
and staining with CCR7 and CD45RA-
specific antibodies. (E) Percentages of
central-memory (CM; CCR7+/CD45RA−)
phenotype cells among Melan-A-specific
T cells of the four treatment groups.
(F) Percentages of effector-memory (EM;
CCR7−/CD45RA−) phenotype cells (n = 5
for patient groups I, III, IV, and n = 6
for patient group II). (A and D) Values
indicate percentages of CD8+ T cells and
of Melan-A-specific T cells. (B, E, and F)
Data shown are mean values per patient,
calculated from the results obtained with
blood samples from all studied six time
points after vaccination, as detailed in the
Supporting Information Fig. 1. ***p<0.001,
**p = 0.001–0.01, and *p = 0.011–0.049,
Mann–Whitney test.
showing that T-cell responses to CpG-based vaccination did not
correlate with patient’s age [18], compatible with a laboratory
study demonstrating that CpG used as vaccine adjuvant can com-
pensate for eventually reduced immune responsiveness in aged
mice [19].
Antibody responses
All 21 patients developed marked humoral immune responses
showing serum Melan-A- and Qb-specific IgG antibodies in ELISA.
Antibody titers in patients of groups I and II were statistically
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Figure 3. Expression of surface receptors by Melan-
A/MART-1-specific T cells. Melan-A-specific T cells
were gated similarly as in Figure 2, and analyzed
for expression of the costimulatory molecules CD27
and CD28, the IL-7 receptor CD127 and the inhibitory
receptor PD-1. (A) Representative dot plot from one
patient out of n = 5–6 for each treatment group,
that is patient 1001 (group I), patient 1009 (group
II), patient 2002 (group III), and patient 2006 (group
IV). As a reference, histograms in the lowest row
show naı¨ve (CCR7+/CD45RA+/tetramer−) and effector
(CCR7−/CD45RA+/tetramer−) phenotype cells, that is
subsets of “antigen-nonspecific” CD8+ T cells from the
representative patient 1009. Values in histograms indi-
cate percent positive cells. (B–E) Statistical comparisons
between the four treatment groups for expression of
(B) CD27, (C) CD28, (D) CD127, and (E) PD-1 by Melan-A-
specific T cells. The data shown in panel B–E are mean
values per patient, calculated from the results obtained
from all studied time points after vaccination, similarly
as for Figure 2. ***<0.001, ** 0.001–0.01, and * 0.011–0.049,
Mann–Whitney test.
significantly higher than titers in patients of groups III and IV, in
accordance to the cellular responses described above (Supporting
Information Fig. 2).
T-cell differentiation
The proportions of Melan-A-specific T cells at the various dif-
ferentiation stages were determined by staining with tetramers,
combined with antibodies specific for the short isoform of CD45
(CD45RA) and the chemokine receptor CCR7 [20]. Double nega-
tive T cells, so-called effector-memory (EM)-phenotype cells, were
significantly increased after IFA adjuvanted vaccination (Fig. 2F).
In contrast, the proportions of central-memory (CM)-phenotype
cells (CCR7+ CD45RA−) were increased in patient groups II and
III who had been treated topically with Imiquimod (Fig. 2E).
Multiparameter flow cytometry allowed simultaneous analysis of
four additional receptors. The two costimulatory molecules CD27
and CD28 are known to be progressively downregulated in CD8+
effector T cells. There was a trend to lower expression of CD27
and CD28 after vaccination adjuvanted with only IFA or only
Imiquimod, but the differences to before vaccination were not
significant (Fig. 3A–C). In accordance with the highest propor-
tions of CM-phenotype cells, Imiquimod was also associated with
the highest frequencies of CD127+ (IL-7R) cells, which was sig-
nificantly higher in comparison to each of the other three patient
groups (Fig. 3D). Finally, we also determined PD-1 expression
by the Melan-A-specific T cells. Interestingly, the mean values in
the first three patient groups were all approximately 32–34% and
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thus significantly higher than before vaccination and higher than
in patient group IV with a mean value of only 14% (Fig. 3E).
Figures 2 and 3 show the patient’s mean values from all time
points after vaccination. Example data from a single time point
(after six vaccinations with MelQbG10) are provided in Support-
ing Information Fig. 3, showing similar differences between the
four patient groups. However, in many instances the differences
did not reach statistical significance, likely due to the low numbers
of samples.
Clinical and PET/CT imaging results
Taking into account all medical and laboratory data acquired dur-
ing the trial, the disease status could be evaluated for 14 of the 21
patients. Not all target lesions could be followed throughout the
9month study period due to surgical excisions and due to different
imaging schedules determined by the investigators. Disease pro-
gression according to the investigator’s judgment was documented
in nine patients: group I 2/5, group II 2/6, group III 3/5, and
group IV 2/5 (see also Supporting Information Table 2). Stable
disease was documented in five patients: group III 2/5 and group
IV 3/5. A follow up evaluation of the disease status was obtained
in April 2010 for all 21 patients. In group I, three patients showed
progressive disease (PD), whereas two patients remained without
evidence of disease. In group II, two patients showed PD whereas
four patients had no evidence of disease. In both groups III and
IV, two patients had died by the time of the follow up, whereas
three patients had no evidence of disease.
Independently from disease status, lymphadenopathy defined
as clinically palpable or radiologically enlarged lymph nodes was
observed in nine patients in average several weeks after study
entry (Supporting Information Table 2). In seven patients, this
lymphadenopathy involved all palpable lymph node regions. In
these seven patients PET/CT-scans showed lymph node enlarge-
ment and increased glucose up-take. In order to excludemetastatic
nodes, fine needle aspirates, and regular clinical follow-up includ-
ing additional imaging and serum S-100 were performed show-
ing no melanoma metastatic cells. Furthermore, these activated
and enlarged lymph nodes were observed in patients without evi-
dence of disease, and/or in body regions that were not affected by
melanoma. Interestingly, in 13 of 15 patients (87%) who under-
went PET/CT imaging, a significantly increased metabolic activ-
ity was seen (SUV = 3.5 ± 1.5 versus 0.92 ± 0.02 g/mL, p =
0.01), predominantly localized in the upper torso in enlarged
lymph nodes (Fig. 4A and B). There was no observed significant
difference in glucose metabolic activity among study groups (p
= 0.17), although the study might have been underpowered to
detect one. Most observed lymph node metabolic activity were
seen in axillary lymph nodes (10/12 or 83%), often bilaterally
and in 2–11 (median 2, interquartile range 2–7) separate lymph
nodes; less often increased activity was seen in inguinal or exter-
nal iliac lymph nodes (4/12 or 33%). We tested if an associa-
tion existed between maximally reached percentages of Melan-A-
specific T cells as well as with the value at PET/CT and the glucose
metabolism reflected by PET/CT SUV, but this could not be con-
firmed (p > 0.7). In one patient, extensive imaging follow-up was
available by PET/CT with three examinations before the first vac-
cination and eight after the full course of vaccination (Fig. 4C).
Significantly increased uptake in PET/CT-measured metabolism
was seen bilaterally in axillary lymph nodes with the two largest
increases in the left axilla (SUV = 6.3 and 3.1 g/mL; Fig. 4C).
Over a period of 870 days, metabolic activity returned to baseline,
with differences still visible at 716 days after the last vaccine injec-
tion in the largest lymph node and at 120 days in the smaller one
(Fig. 4C).
Tumor tissue from patients with relapse
In 8 patients tumor tissue from skin and subcutaneous lesions was
collected prior and after vaccination. We analyzed the expression
of Melan-A and HLA-class I (Fig. 5 and Supporting Information
Table 2). Diminished expression of Melan-A or HLA-class I was
defined by more than 50% reduced staining of intensity. This was
the case for Melan-A in 4/8 patients (one patient in group II, two
patients in group III and one patient in group IV) and for HLA-class
I in 2/8 patients analyzed (one patient in group I and one patient
in group III; Fig. 5D).
Discussion
In this trial, we analyzed the T-cell induction properties and
the safety profile of MelQbG10 when combined with dif-
ferent adjuvants (IFA, Imiquimod 5%) and/or administered
by different routes (s.c., i.d., and i.n.). The vaccinations
were well tolerated; there were no major toxicities. We did
not observe autoimmune-related reactions, in contrast to the
recently introduced immunotherapy with anti-CTLA-4 antibody
(Ipilimumab) [21]. As expected, there were in part intense and
persistent local reactions, particularly in patients who received
IFA [22,23]. Furthermore, we observed (multi-) regional lym-
phadenopathy. Interestingly, this was associated with in part
high up-take of glucose detected in PET/CT scans, mimick-
ing metastatic involvement. This phenomenon can also be
termed pseudo-progression. It reflects a significant activation
of vaccine site draining lymph nodes. Similar reactions have
already been observed with IFN-α treatment [24] and with
Ipilimumab.
VLPs are very efficient in eliciting antibody responses, and thus
frequently used for various vaccine purposes [25]. Therefore, it
was not surprising that anti-Melan-A antibodies were induced
efficiently. It is likely that the observed anti-Melan-A antibod-
ies are directed to several B-cell epitopes of the long Melan-A
peptide used for vaccination. Possibly, some of these epitopes
may overlap with the sequence of amino acids 26–35 represent-
ing the A2/Melan-A T-cell epitope. Besides antibodies and CD4
T-cell responses [11], VLPs can also trigger CD8+ T-cell responses.
It is generally acknowledged that clinically useful T-cell responses
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Figure 4. PET/CT imaging showing enlarged lymph nodes and increased glucose metabolism after vaccination. Fifteen of the 21 patients of
this study underwent PET/CT imaging. In parallel to the assessment of disease development (not shown), immune activation was evaluated by
measuring the glucose metabolism in vaccine-site draining lymph nodes. (A) Patient 2002 (group III) with bilateral axillary lymph nodes with one
that is enlarged (arrow). Images: Maximal intensity projection (left) with PET/CT fusion image (top), PET image (middle), and CT image (bottom).
(B) Patient 2004 (group III) with multiple bilateral axillary (arrow, horizontal arrowhead) and subclavicular (vertical arrowhead) lymph nodes with
increased glucose metabolism. (C) Patient 1003 (group I) with long-term longitudinal follow-up before and after the seven vaccinations injected
between the third and fourth PET/CT studies. The standardized uptake value (SUV) was measured in two axillary lymph nodes (LN1, LN2) from
patient 1003 (group I) before and after the last vaccination (right). Note also the local inflammation in vaccination sites in the proximal right and
left arms and left thigh (left).
are much more difficult to generate as compared to antibody
responses. Therefore, T-cell vaccines are much less advanced as
opposed to B-cell vaccines. Numerous academic and industrial
teams undertake multiple research and development efforts, in
order to elucidate the precise biological parameters that need to
be considered for generating T-cell responses that are capable to
protect from infectious or malignant disease. In this mindset, we
are optimizing VLP-based vaccines.
In a previous study in melanoma patients, we have shown that
MelQbG10 can trigger ex vivo detectable and thus relatively strong
tumor-specific CD8+ T-cell responses [10]. The present study
was based on the same vaccine (MelQbG10), but extended by
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Figure 5. Reduced HLA-class I and Melan-A/MART-1 expression after vaccination. Immunohistochemistry images (×8 magnification) of different
tumor biopsies before (left) and after (right) vaccination showing reduced Melan-A or HLA-class I expression. (A) Tumor biopsies from plantar left
(primary tumor, left) and left leg (in transit cutaneous metastasis, right) with high (left) and low (right) Melan-A intensity staining (Patient 2010,
group IV). (B) Biopsies of two dermal abdominal metastases, with high (left) and low (right) Melan-A intensity staining (Patient 2001, group III). (C)
Cutaneous metastasis of the right knee (right and left) with low HLA-class I intensity staining (Patient 1003, group I). (D) Melan-A and HLA-class I
expression before and after vaccination, for each evaluable patient (n = 8) are shown.
additional components. The addition of IFA resulted in signifi-
cantly increased T-cell frequencies. These responses were domi-
nated by EM-phenotype cells, that is CD45RA−CCR7− cells. These
cells were also mostly CD127 (IL-7R) negative, demonstrating
that IFA primarily induced effector-phenotype cells, with only
low proportions of memory-phenotype cells. These results are
reminiscent of vaccines composed of synthetic peptide, CpG-
ODN, and IFA, which are also dominated by EM-phenotype CD8+
T cells [26]. In contrast, our data show that increased percent-
ages of CM-phenotype cells (CD45RA−CCR7+) with enhanced
expression of CD127 were induced by the addition of Imiquimod.
Thus, triggering TLR-7 by Imiquimod may promote memory dif-
ferentiation, which is promising because memory cells are known
to increase the protective potential of T-cell responses [27–29].
Despite its importance, memory cell triggering is often insuffi-
cient by synthetic vaccines. The mechanisms by which TLR-7 may
promote memory cell activation are likely linked to DC activa-
tion via TLR-7. The generation of memory cells may depend on
Wnt-TCF-1, mTor, and AMPK signaling pathways [27–29]. Our
data point to possible connections between these mechanisms and
TLR-7 induced pathways.
Our previous study showed that even without topical
Imiquimod vaccination with MelQbG10 induced increased per-
centages of CM-phenotype cells [10]. Here, we show that the com-
bination of MelQbG10 plus Imiquimod and IFA (thus triggering of
TLR-7 and -9) leads to enhance promotion of memory-phenotype
cells. However, we have never tested whether this can be achieved
by triggering of TLR-7 without TLR-9, since MelQbG10 always
contained the CpG-ODN G10.
Recent literature reported that the combined stimulation
of multiple innate immune receptors may enhance vaccine
efficacy [30], reminiscent to the notion that pathogens may trig-
ger innate immunity due to the expression of multiple microbe-
associated molecular patterns (MAMPs). However, there are still
considerable limitations in the availability of clinically graded
drugs for triggering innate immune receptors. Imiquimod is a
skin cream and can only be applied topically. It will be inter-
esting to test whether systemic and thus more efficient TLR-7
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triggering can promote even higher numbers of CM-phenotype
cells.
The frequencies of Melan-A-specific T cells after vaccination
with MelQbG10 plus Imiquimod were relatively low. In contrast,
the addition of IFA resulted in higher frequencies. Thus, combin-
ing CpG-ODN, Imiquimod, and IFA achieved both memory- and
effector-phenotype cells, with relatively high frequencies and high
proportions of CM-phenotype cells. However, our data are pre-
liminary due to the low numbers of patients, and thus require
further confirmation.
Even though the percentages of tetramer positive T cells were
relatively low, they actually revealed large numbers of tumor-
specific T cells, because we analyzed the blood samples directly
ex vivo. In many cancer vaccine studies, T cells are analyzed after
they have proliferated in tissue cultures for one or several weeks,
providing results with higher T-cell percentages but precluding
precise conclusions on T-cell numbers and qualities in vivo [12].
Therefore, recent cancer vaccine studies increasingly include anal-
ysis of T cells directly ex vivo [31–38]. Because of considerable
inter-patient variability of frequencies of tumor-antigen-specific
T cells, at baseline and after immunotherapy, it is important to
determine how many patients are “immune–responders”, based
on the comparison of their values before versus after vaccina-
tion. Data from direct ex vivo analysis show that the majority of
vaccination strategies were able to trigger responses of Melan-A-
specific CD8+ T cells but usually not in all patients [31–38]. For
example, a recent study by Ribas et al. showed T-cell responses
in about 50% of melanoma patients vaccinated with DNA fol-
lowed by peptides, a novel prime-boost approach [36]. The results
of our present study with 16/21 immune responder patients
is favorable, particularly when focusing on the 11 patients in
whom vaccination included IFA (groups I and II) who all showed
ex vivo detectable T-cell responses. However, the T-cell fre-
quencies remained lower than in patients vaccinated with pep-
tide + CpG 7909 (PF-3512676) emulsified in IFA [18,26], rais-
ing the possibility that B-type CpGs (e.g. 7909) may be supe-
rior to A-type CpGs (e.g. G10) for CD8+ T-cell vaccination in
humans. Definitive conclusions depend on trials directly com-
paring the various vaccination approaches. Importantly, clinical
efficacy needs to be tested in large-scale trials. The currently
available evidence of clinical benefit of CpG-based vaccines [18]
justify evaluating their clinical usefulness in phase III
studies.
We developed MelQbG10 several years ago, and used the ana-
log peptide sequence ELAGIGILTV with L instead of A at position 2
as compared with the natural sequence EAAGIGILTV. As for other
analog peptides, we found that this analog peptide triggered rel-
atively high frequencies of T cells. However, more recently we
found that T-cell responses were more robust after vaccination
with the natural peptide, since the T cells were more strongly
activated and were of higher functional avidity as compared with
T cells after vaccination with the analog peptide [39]. Therefore,
it is preferable to vaccinate with peptides corresponding to native
tumor antigens. Unfortunately, such peptides are often insuffi-
ciently antigenic, particularly when cross-presentation is required
such as for long peptides as used in this study. Therefore, immu-
nization with analog peptides is still justified since reasonably
large fractions (>50%) of the induced T cells can recognize tumor
cells [39]. The question whether the native or the analog Melan-A
peptide should be used for T-cell analysis is much easier to answer.
Tetramers constructed with the Melan-A analog peptide are “uni-
versal,” as they readily bind virtually all T cells induced by analog
or natural peptide, but also endogenously by the tumor itself [39].
Thus, A2/Melan-A tetramer binding is highly cross-specific and
does not discriminate between the very fine differences in speci-
ficity and affinity depending on vaccination with analog versus
native antigen.
Of interest, PET/CT could evidence increased lymph node
activity in the majority of the patients, as a way of show-
ing increased activity in relation to inflammation and immune
response, even in the long term (>4 months). This has not been
utilized in vaccine studies so far. It has rather been described as
an epiphenomenon in relation to the last vaccination campaigns
against influenza A/H1N1 pandemic as seen in patients under-
going oncologic PET/CT [40–42] or in sporadic immunization
cases [43,44]. Increased glucose metabolism in lymph nodes was
not observable>14 days after immunization in the study by Burger
et al. [42] or >30–50 days by Thomassen et al. [41], possibly due
to the shorter stimulation time of these vaccines as opposed to
the vaccine formulations used in the present study. Interestingly,
Iyengar et al. [45] found an association between PET-measured
lymph node signals and viremia in HIV-infected patients that
was attributed to CD4 lymphocyte activation in relation to HIV
replication. They observed a predominance for upper torso lymph
nodes in recently and chronically HIV-infected patients, but not in
their control group of healthy non-HIV-infected volunteers under-
going killed influenza vaccination, where it was observed only
on the upper torso of the injection site. In future trials, PET/CT
could be an attractive way to noninvasively monitor and investi-
gate inflammatory and immune responses to vaccination, although
the exact mechanisms and significance of the increased glucose
metabolism remain to be investigated.
In summary, MelQbG10 can be considered safe and well tol-
erated when given at a cumulative dose of 6 mg (6 × 1 mg).
The use of IFA resulted in more frequent side effects, but
induced the highest Melan-A-specific T-cell frequencies. Both
memory- and effector-phenotype T-cell responses were observed
when MelQbG10/IFA vaccines were given in combination with
Imiquimod. Our data suggest that the induced immune activa-
tion was biologically relevant because several relapsing melanoma
lesions demonstrated diminished expression ofMelan-A or of HLA-
class I, presumable reflecting mechanisms of immune escape [46].
Future vaccines need to target multiple antigens and HLAs simul-
taneously.
Vaccine components need to be tested in humans, in order
to determine which of them, and what type of final vaccine for-
mulations are most promising for further and large scale clin-
ical development. We used the A-type CpG-ODN G10 that we
had integrated in our VLPs, resulting in sizable T-cell responses,
which were however less powerful than in rodents [10]. In the
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present paper, we combined this approach with additional adju-
vants and/or varied the administration route and found quantita-
tively and qualitatively different T-cell responses. The next steps
will be to replace some components, by using, for example a B-type
CpG-ODN, and/or by supplementation with (parenteral) drugs
that trigger additional TLRs and further innate immune receptors.
With a step-by-step approach, we will learn which type of vaccine
formulation is optimal for triggering CTL and Th1 responses with
the potential of clinical benefit for cancer patients.
Materials and methods
Patients and trial design
Eligible patients were at least 18-years old, with histologically con-
firmed stage III or IV malignant melanoma (AJCC), HLA-A*0201
positivity, and an expected survival of at least 9 months. The cur-
rent general health condition had to allow the patient to undergo
all study procedures according to the protocol. Main exclusion cri-
teria were known or planned pregnancy or lactation, use of any
investigational drug, and previous participation in a clinical trial
with a Qb-based vaccine. The first patient was enrolled in May
2008, the last in December 2009. All patients provided written
informed consent before any study-specific procedure was per-
formed.
The exact composition of MelQbG10 was reported earlier [10].
The first treatment group (group I) received three initial sub-
cutaneous (s.c.) injections of 1 mg MelQbG10 mixed with IFA
(Montanide ISA-51, Seppic GmbH, Koeln, Germany) in weekly
intervals, followed by three monthly injections with the vaccine.
The second treatment group (group II) was vaccinated identi-
cally to the first group but was additionally treated with top-
ical Imiquimod 5% cream (AldaraTM, 3M, Switzerland) once
daily for 10 days (with 2 days of treatment pause after the first
5 days). The cream was applied with a thin layer on the injection
site and covered an area of 5 × 5 cm. The third group (group III)
received three intradermal (i.d.) injections of 1 mg MelQbG10 in
weekly intervals, followed by threemonthly intradermal injections
with MelQbG10. In addition, the patients were treated with a thin
layer of Imiquimod 5% cream once daily as described for group II.
The fourth treatment group (group IV) received three ultrasound-
guided intranodal (i.n.) injections of MelQbG10 initially starting
with 14 μg, then 42 μg, and thereafter 140 μg in weekly inter-
vals, followed by three monthly injections of 140 μg MelQbG10.
All treatment groups received a final boost 4 weeks after the last
vaccination with the Melan-A/MART-1 peptide plus IFA s.c (for
more details on trial design see Supporting Information Fig. 1).
Before starting treatment group II (Imiquimod + IFA) an inter-
nal safety data review was performed with respect to treatment
group III (i.d. injection + Imiquimod). Local ethic review com-
mittees and responsible health authorities approved the study,
which was performed according to GCP guidelines and registered
at http://www.ClinicalTrials.gov: NCT00651703.
Assessment of safety and tolerability and clinical
results
Adverse events (AEs), concomitant medication, vital signs, physi-
cal examinations, ECGs, antinuclear antibodies, and routine clin-
ical laboratory blood and urine analyses were monitored care-
fully at defined visits. Local reactions at the injection sites were
recorded by patients and investigators. Patients were asked to
record local reactions after every injection of study medication in
a paper-based diary for a period of 3 days. Pain and itching were
documented; swelling, and induration were assessed by record-
ing the reactions’ diameter if the diameter was > 1 cm. Local
reactions that required medical intervention were documented as
AE. Safety and tolerability parameters were primarily evaluated
within the single subject and compared with baseline, in addi-
tion, trends between the four groups were analyzed. In total 21
melanoma patients have been included and represented the safety
population, which was identical to the full analysis set. No data
have been extrapolated.
The status of the disease was monitored clinically and/or by
computer tomography (CT) at screening and at the end of the
trial, if clinically indicated a fluorodeoxyglucose-positron emis-
sion tomography (FDG-PET/CT) was performed (GE Healthcare,
Milwaukee, WI, USA). To compare PET/CT imaging results,
we used the maximal standardized uptake value (SUV in
g/mL) corrected for body weight as a way to reflect glucose
consumption.
Immune monitoring and immunohistochemistry
Primary goal of the clinical trial was to achieve efficient Melan-A-
specific T-cell responses by enhancing the immuno-stimulating
potential of MelQbG10 with various adjuvants and different
administration modes in patients with malignant melanoma.
Simultaneous enumeration and phenotyping of antigen-specific
CD8+ T cells was achieved by flow cytometry and were ana-
lyzedwith FlowJoTM software (TreeStar). Ficoll-Paque centrifuged
PBMC (1–2 × 107) were cryopreserved in RPMI 1640, 40%
FCS, and 10% DMSO. Phycoerythrin-labeled HLA-A*0201/Melan-
A/MART-1 A27L peptide26–35 (ELAGIGILTV) tetramers were pre-
pared as described [17]. Anti-CD8, -CD28, -PD-1, and anti-CCR7
mAbs were purchased from BD PharMingen (San Diego, CA,
USA), anti-CD45RA from Beckman Coulter (Brea, CA, USA), and
anti-CD27 and -CD127 from eBioscience (San Diego, CA, USA).
All tetramer and antibody batches were titrated to determine
optimal reagent concentrations. PBMC were thawed, and CD8+
T cells were enriched using a MiniMACS device (Miltenyi Biotec,
Bergisch Gladbach, Germany) resulting in >90% CD3pos CD8pos
cells. Cells (106) were incubated with tetramers (1 μg/mL,
60 min, 4◦C) and then with antibodies (30 min, 4◦C). For dead
cell exclusion, cells were stained with Live/Dead Fixable Dead
Cell violet stain (Molecular Probes/Invitrogen). A total of 5 × 105
CD8+ T cells/sample were acquiredwith a flow cytometry LSR IITM
machine. The cytometer performance was checked daily using the
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CST (BDTM Cytometer Setup and Tracking) quality control beads
system according to the manufacturers’ instructions. To evaluate
whether the CD8 T cells from the 21 patients of this study were
representative for larger numbers of patients, we compared their
pre-vaccination values to those of 37 untreated patients, also with
stage III–IV metastatic skin melanoma, which we have recently
studied with an identical flow cytometry approach. For all param-
eters studied (Melan-A tetramer, CD27, CD28, CD127, PD-1, and
effector-memory-phenotype and central-memory-phenotype cells)
there were no statistical differences (data not shown). Results of
tetramer + T cells were calculated and are indicated in percent-
ages of circulating CD8+ T cells. Results from T-cell phenotyping
were only used when the numbers of tetramer positive events were
at least 20.
Biopsies of metastases were stained for the melanocytic dif-
ferentiation antigen and HLA-class I before and after the treat-
ment. For immunohistochemistry the paraffin-embedded tumor
tissue sections obtained at different time points prior and after
vaccination were stained with anti-Melan-A/MART-1 monoclonal
antibody A103 (Novocastra Laboratories Ltd., Newcastle upon
Tyne, UK) [9] and with anti-HLA-class I antibody 3F10 (1:1000;
RDI Research Diagnostics, Inc., Concord, MA, USA) [47]. The
quantification was done by an experienced, board-certified der-
matopathologist (RD) on a Zeiss Axiophot HAL100 (Carl Zeiss
Microimaging GmbH, Switzerland) with ×40 magnification.
Immunoreactivity, evaluated as intensity of the staining in rela-
tionship to normalmelanocytes in the epidermis (internal control),
was scored semiquantitatively in percentages (0–100%). A clear
cut difference, interpreted as diminished expression of Melan-A or
HLA-class I, was considered starting from a change of 50% ormore
in the comparison of the sections prior to and after vaccination, as
illustrated in Figure 5. Because of expression heterogeneity [9],
we analyzed three high power fields of all lesions.
Data and statistical analysis
Evaluation of the disease status was described for each patient
individually. AEs were coded using MedDRA Version 12.0. Sum-
mary tables were presented by frequency of AEs and by patient.
AEs were listed by subject, including verbatim term, coded Med-
DRA term, severity, and relationship to treatment. Standard labo-
ratory measurements, vital signs, and ECG parameters were listed
by subject and time point of collection. Out of normal range and
clinically significant deviating values were summarized by descrip-
tive statistics. Anti-Melan-A-specific T cells were expressed as %
tetramer positive cells of total CD8+ T cells. Immune responders
were defined as patients whose maximal T-cell frequency at any
time point during the trial was at least double the preimmune
T-cell frequency. T-cell frequencies below 0.01% were consid-
ered as not detectable (threshold) [17]. Statistical significance
was assessed by the nonparametric Mann–Whitney and Kruskal–
Wallis tests or the parametric Student’s t-test where appropriate.
Associations were tested using nonparametric Spearman rank cor-
relation. P values less than 0.05 were considered significant and
reported in the figures. The scatter dot plots in Figure 2 and 3
show individual values, mean values, and standard deviations.
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